Risk factors

The risk section is dominated by completing the proposed GOWell business combination before the August 14, 2026 deadline.

Company is a blank check company formed to complete an initial business combination in asset management, leisure, or hospitality.

LENZ transitioned from a clinical-stage biotech to a commercial-stage company following FDA approval and U.S. launch of VIZZ for presbyopia.

Lease commitments and related restrictive covenants now pose primary operational and financial risks for Comstock Inc. Common stock share count increased to 51,853,490 shares at December 31, 2025.

Neurogene added healthcare reform risks and warned of potential U.S. tariffs on imported pharmaceuticals.

Borrowing capacity and credit facility compliance remain central operational hurdles given ongoing annual losses in 2025 and 2024. Federal government contracts expose the company to evolving administrative policies, workforce reductions, and international tariff tensions.

Clinical stage biotech with accumulated deficit of $99.6 million dependent on PLX-200 and PLX-300. Programs focus on rare pediatric lysosomal storage disorders facing intense competition. Substantial doubt about ability to continue as a going concern.

New disclosures highlight heightened scrutiny on foreign land ownership, animal housing regulations, and information security risks.

Sanara MedTech dropped risks concerning its value-based wound strategy and expanded market entry. Patent protection details for CellerateRX Surgical were updated. Regulatory and R&D disclosures were revised.

Silver Pegasus Acquisition Corp. is a blank check company formed to complete an initial business combination.

VirnetX reported a net loss of $18.2 million for 2025, bringing its accumulated deficit to $222.9 million.

VenHub Global is an early-stage company developing autonomous smart stores relying heavily on AI and imported components from China. Operations are heavily controlled by CEO Shahan Ohanessian and Chairwoman Shoushana Ohanessian via SSO, LLC. The company faces material weaknesses in internal controls and substantial executive cash compensation obligations.